Hyfe

Do not select Hyfe if:

• You require an FDA-cleared cough counting device immediately for a regulated clinical workflow (the CoughMonitor Suite is not FDA-cleared based on public statements).
• Your study design requires raw audio storage for auditability or re-labeling (Hyfe's stated approach emphasizes event timestamps rather than raw audio retention).
• You need transparent, self-serve enterprise pricing for rapid procurement comparisons.
• Broad third-party review platform coverage (e.g., G2/Capterra) is a key factor in vendor selection; Hyfe has limited presence on those platforms.
• You are a consumer unwilling to pay a subscription and require a permanent free tier; some users reported dissatisfaction after a free-to-paid product change.

Representative user feedback includes both positive and negative themes.

Representative positive feedback highlights accurate tracking and clear data presentation. Representative negative feedback centers on dissatisfaction with the transition from a free model to a paid subscription; vendor support channels offer data export options to address continuity concerns.

App Store presence shows a generally favorable rating band with limited review volume compared with mainstream consumer apps; this sample-size limitation can skew sentiment impressions.

A peer-reviewed paper reports evaluation across multiple hours of continuous audio with several thousand cough events, concluding strong sensitivity alongside a measurable false positive rate.

Critical evaluation:

• Strength: peer-reviewed analysis with extended continuous recordings across multiple etiologies.
• Limitation: limited participant diversity for broad generalizability; additional evidence would be useful for pediatric populations, unusual environments, or rare cough phenotypes.

• Company size: mid-to-large pharma and biotechs; CROs supporting late-phase trials; academic centers running investigator-initiated studies.
• Industries: respiratory therapeutics, chronic cough drug development, ILD/IPF, asthma/COPD, infectious disease monitoring research.
• Personas: clinical operations leaders, digital biomarkers teams, biostatisticians (endpoint design), medical affairs, data management.
• Pain points: need for objective cough endpoints, desire to reduce manual cough counting burden, and a requirement for longer monitoring windows.

Hyfe provides AI-based passive cough detection and continuous cough counting. Its offerings include:

• Life sciences / clinical trials: continuous cough measurement as a digital endpoint (CoughMonitor Suite).
• Consumer cough tracking: a subscription app (CoughPro) for individuals with chronic cough who want longitudinal tracking, insights, and content.
• Virtual care / remote patient monitoring (RPM) concepts: positioning cough frequency as a remotely monitored signal for chronic respiratory conditions.

Hyfe's primary capability is continuous cough quantification in real-world environments without requiring manual user input. Processing is described as occurring on-device and raw audio retention is minimized.

Hyfe operates in two distinct markets with different buyers:

1. B2B (primary revenue driver, based on product emphasis): pharma sponsors, CROs, digital biomarker teams, and academic investigators who require cough frequency endpoints in trials (COPD, asthma, ILD/IPF, chronic cough, etc.).
2. B2C (adjacent): individuals with chronic cough using CoughPro for self-management and tracking.

Vendor materials position the product as clinically validated continuous cough monitoring; buyers should evaluate the underlying evidence and scope of validation when assessing fit.